~~<i id='57F324D3C8'><strike id='57F324D3C8'><tt id='57F324D3C8'><pre id='57F324D3C8'></pre></tt></strike></i>~~

Home» leisure time» entertainment

entertainment

author：knowledge 2025-10-02 06:27:01 Page View：8262

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： EU regulator recommends expanding Mounjaro approval to obesity
Next article： Alkermes shareholders re

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

NIH director takes cautious approach to Biden drug pricing priority

NIHDirectorMonicaBertagnolliKevinDietsch/GettyImagesWASHINGTON—PresidentBidenhaspromisedtorequirefai

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

The surgeon had a dilemma only a Nazi medical text could resolve

GermantroopsandartilleryparadethroughthestreetsofVienna,afterHitlerhadenteredthecity,March1938.Londo